YTH domain–containing family protein 1 (YTHDF1), a reader of N6-methyladenosine (m 6 A), has been implicated in regulating RNA metabolism in the cytosol. Here, we report a role of YTHDF1 within the nucleus in response to genotoxic stress. Upon radiation, YTHDF1 is phosphorylated at serine-182 in an ataxia telangiectasia and Rad3-related–dependent manner. This phosphorylation inhibits exportin 1–mediated nuclear export of YTHDF1, resulting in its accumulation within the nucleus. Nuclear YTHDF1 enhances the binding capacity of serine- and arginine-rich splicing factor 2 to a group of m 6 A-modified exons, leading to increased exon inclusion. Specifically, YTHDF1 promotes splicing and expression of DNA repair genes, such as BRCA1 and TP53BP1 , thereby mitigating excessive DNA damage. Depletion of YTHDF1 sensitizes cancer cells to radiation treatment. Together, our study reveals a crucial role of YTHDF1 in m 6 A-mediated messenger RNA splicing in the DNA damage response, proposing it as a potential target for radiation therapy.
The global rise in obesity and its associated metabolic disorders underscores the need for a deeper investigation into their underlying molecular mechanisms. While genetic factors are well-established contributors, recent research has increasingly focused on epigenetic regulators, particularly N6-methyladenosine (m6A)—the most prevalent internal RNA modification in eukaryotes. This post-transcriptional modification plays a crucial role in RNA metabolism by regulating mRNA stability, splicing, nuclear export, and translation efficiency. Notably, emerging evidence implicates m6A in both adipogenesis and metabolic dysregulation. In this review, we systematically examine three key dimensions: (1) the molecular mechanisms of m6A modification, including writers, erasers, and readers, in obesity; (2) dysregulated m6A patterns in obesity-related pathologies, such as type 2 diabetes (T2D), insulin resistance, metabolic dysfunction-associated steatotic liver disease (MASLD), and the glycolysis in cancer cells; and (3) the therapeutic potential of targeting m6A and the regulators. By critically assessing recent advancements, we highlight m6A’s dual role as both a metabolic sensor and a disease modulator, offering novel insights into potential strategies for combating obesity-related metabolic syndromes.
Obesity is a chronic metabolic disorder and a growing global public health challenge, affecting hundreds of millions of individuals worldwide. While diet and physical activity are well-established contributors, increasing evidence underscores the critical role of epigenetic mechanisms in mediating obesity-related processes. Epigenetic modifications—such as DNA methylation, RNA methylation (particularly N6-methyladenosine), histone modifications, non-coding RNAs, and chromatin remodeling—modulate gene expression without altering the DNA sequence. This review aims to provide an overview of the epigenetic mechanisms involved in obesity, with an emphasis on their molecular functions and regulatory networks. Integrating findings from relevant studies, we discuss how these modifications influence obesity-related outcomes through regulating key processes such as adipocyte differentiation and energy metabolism. Advancing our understanding of epigenetic regulation may pave the way for novel, targeted strategies in the prevention and treatment of obesity.
Per- and polyfluoroalkyl substances (PFAS) are a class of synthetic fluorinated chemicals characterized by high environmental persistence and widespread occurrence, which have attracted increasing attention due to their potential adverse effects on human health. As the global burden of chronic diseases related to lipid and glucose dysregulation rises, identifying environmental contributors is increasingly important. Growing evidence links PFAS exposure to metabolic disorders, particularly those involving lipid and glucose metabolism. This review summarizes current findings on the mechanisms by which PFAS disrupt metabolic balance, with a focus on pathways involved in fatty acid uptake and oxidation, nuclear receptor signaling, oxidative stress, inflammation and insulin signaling. Furthermore, we highlight the convergence of molecular pathways involved in PFAS-induced lipid and glucose metabolic alterations, which may provide a mechanistic basis for understanding the development of metabolic disorders. Finally, we discuss current research limitations and future perspectives, including the potential application of computational approaches and emerging technologies to further elucidate PFAS-related metabolic effects. A comprehensive understanding of these mechanisms may help identify targets for the prevention and treatment of metabolic diseases, including obesity and type 2 diabetes, and provide regulatory policies on PFAS.
11 December 2025 in Biochemical and Biophysical Research Communications